Heron Therapeutics, Inc.

NASDAQ:HRTX

Biotechnology

Healthcare
$0.27 +3.74%

+$0.01 today

Market cap
$51.94M
Beta
1.57
P/E (TTM)
-2.5
EPS (TTM)
-$0.16
52W Low $0.38High $2.30

Volume 1.81M

Average 2.90M

HRTX Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Heron Therapeutics, Inc.NASDAQ: HRTX

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) growth accelerates

Q1 FY2026 weighted avg shares (diluted) of 189.65M shares rose 23.6% year over year, ahead of the +11.3% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 13.8% from the prior quarter. Over 3 fiscal years it compounded at +15.2% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +23.6% holds above the trailing-twelve-month pace of +11.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
189.65M+13.8% QoQ
Last fiscal yearDec 2025
166.71M+9.4% YoY
LTMMar 2026
170.18M+11.3% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+23.6%——
1 year+9.4%——
3-year CAGR+15.2%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
166.71M USD
Year-over-year change
+9.4%
4-year CAGR
+14.1%

Weighted Avg Shares (Diluted) vs competitors

How HRTX compares with its peers on the latest reported figures

  • HRTX's LTM Mar 2026 weighted avg shares (diluted) of 170.18M shares is the 3rd highest of the 10 companies compared; the peer median is 80.92M shares.
  • Its year-over-year change of +11.3% is the 7th highest of 9, against a peer median of +21.2%.
  • Over three fiscal years its annual growth of +15.2% compares with a peer median of +22.5%.
HRTX Competitors Peer median
Weighted Avg Shares (Diluted) for HRTX and competitors
Company Period LTM YoY 3-year CAGR
IVVDInvivyd, Inc.LTM Mar 2026193.02M +61.8%+16.7%
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026179.3M +94.5%+77.8%
HRTXHeron Therapeutics, Inc.LTM Mar 2026170.18M +11.3%+15.2%
CHRSCoherus Oncology, Inc.LTM Mar 2026122.27M +6.0%+15.7%
OABIOmniAb, Inc.LTM Mar 2026119.25M +15.1%+10.0%
PLXProtalix BioTherapeutics, Inc.LTM Mar 202680.92M +3.7%+17.5%
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 202645.37M +27.3%+27.5%
TARAProtara Therapeutics, Inc.LTM Mar 202643.36M +56.7%+56.1%
NTHINeonc Technologies Holdings, Inc.LTM Mar 202620.19M ——
MDWDMediWound Ltd.LTM Mar 202611.89M +14.9%+31.6%
Peer median (excluding HRTX) 80.92M+21.2%+22.5%

Competitors are the stored peer set for HRTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue86.35M107.67M127.04M144.29M154.9M
Cost of Revenue46.02M54.87M65.11M38.65M41.35M
Gross Profit40.33M52.8M61.94M105.64M113.56M
Gross Margin46.7%49.0%48.8%73.2%73.3%
Research & Development130.82M82.7M39.13M16.68M12.43M
Selling, General & Admin127.33M144.75M119.82M100.48M103.67M
Operating Expenses258.15M227.46M172.55M117.17M116.1M
Depreciation & Amortization3.02M2.89M2.9M2.49M2.31M
EBITDA(215.25M)(176.66M)(103.79M)(5.06M)(17.88M)
EBITDA Margin-249.3%-164.1%-81.7%-3.5%-11.5%
Operating Income(217.83M)(174.66M)(110.62M)(11.53M)(2.54M)
Operating Margin-252.3%-162.2%-87.1%-8.0%-1.6%
Interest Income433K1.64M3.36M3.55M0
Interest Expense2.41M2.47M3.87M6.03M0
Other Income / Expenses(2.86M)(7.37M)56K(2.05M)(17.66M)
Income Before Tax(220.68M)(182.02M)(110.56M)(13.58M)(20.2M)
Pre-Tax Margin-255.6%-169.1%-87.0%-9.4%-13.0%
Income Tax Expense00000
Net Income(220.68M)(182.02M)(110.56M)(13.58M)(20.2M)
Net Margin-255.6%-169.1%-87.0%-9.4%-13.0%
EPS (Basic)(2.24)(1.67)(0.80)(0.09)(0.12)
EPS (Diluted)(2.24)(1.67)(0.80)(0.09)(0.12)
Weighted Avg Shares98.47M109M138.14M152.45M166.71M
Weighted Avg Shares (Diluted)98.47M109M138.14M152.45M166.71M

Heron Therapeutics, Inc.

NASDAQ:HRTX

Intrinsic Alpha fair value

Locked

Current Price

$0.27

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.